PARVOLEX LIQ IV 200MG/ML DIN 02094738
Health Canada record
| Active ingredient(s) | ACETYLCYSTEINE 200 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intravenous |
| Schedule | NON-PRESCRIPTION DRUGS |
| Class | Human |
| ATC | R05CB01 ACETYLCYSTEINE |
| Original market date | 31-Dec-1994 |
| Current status date | 08-Nov-1996 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ACETYLCYSTEINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02534908 | ACETYLCYSTEINE INJECTION | EUGIA PHARMA INC. | Solution | ACETYLCYSTEINE 200 MG | Approved |
| 02528274 | ACETYLCYSTEINE INJECTION | AURO PHARMA INC | Solution | ACETYLCYSTEINE 200 MG | Approved |
| 02243098 | ACETYLCYSTEINE SOLUTION | SANDOZ CANADA INCORPORATED | Solution | ACETYLCYSTEINE 200 MG | Marketed |
| 02459906 | ACETYLCYSTEINE SOLUTION USP | HIKMA CANADA LIMITED | Solution | ACETYLCYSTEINE 200 MG | Marketed |
| 02538431 | ACETYLCYSTEINE SOLUTION USP | STERIMAX INC | Solution | ACETYLCYSTEINE 200 MG | Marketed |
| 02300435 | ACETYLCYSTEINE INJECTION | TELIGENT OU | Solution | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 02091526 | MUCOMYST | WELLSPRING PHARMACEUTICAL CANADA CORP | Solution | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 00606235 | MUCOMYST INJ 200MG/ML | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | Liquid | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
| 02181460 | PARVOLEX | MYLAN PHARMACEUTICALS ULC | Liquid | ACETYLCYSTEINE 200 MG | Cancelled Post Market |
International API supply for ACETYLCYSTEINE
11 valid EDQM Certificates of Suitability from 10 holders. 7 active FDA Drug Master Files.
Request a quote for PARVOLEX LIQ IV 200MG/ML